These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7915991)

  • 1. Sensitivity of dopamine D2 receptors following long-term treatment with roxindole.
    Seyfried CA; Bartoszyk GD
    Eur J Pharmacol; 1994 May; 257(1-2):67-72. PubMed ID: 7915991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD; Harting J; Minck KO
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roxindole, a potential antidepressant. I. Effect on the dopamine system.
    Maj J; Kolodziejczyk K; Rogóz Z; Skuza G
    J Neural Transm (Vienna); 1996; 103(5):627-41. PubMed ID: 8811507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the interaction of roxindole with brain monoamine oxidases and dopaminergic neurones in vitro and in vivo.
    Seyfried CA; Adam G
    Pharmacol Toxicol; 1994 Jun; 74(6):314-20. PubMed ID: 7937563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presynaptic dopamine receptors: insensitivity to kainic acid and the development of supersensitivity following chronic haloperidol.
    Bannon MJ; Bunney EB; Zigun JR; Skirboll LR; Roth RH
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Jun; 312(2):161-5. PubMed ID: 6772975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
    Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
    J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.
    Koener B; Goursaud S; Van De Stadt M; Calas AG; Jeanjean AP; Maloteaux JM; Hermans E
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):65-77. PubMed ID: 21061116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of buspirone on dopamine dependent behaviours in rats.
    Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
    Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation.
    Marin C; Chase TN
    Eur J Pharmacol; 1993 Feb; 231(2):191-6. PubMed ID: 8095897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double dissociation of the effects of haloperidol and the dopamine D3 receptor antagonist ABT-127 on acquisition vs. expression of cocaine-conditioned activity in rats.
    Banasikowski TJ; Bespalov A; Drescher K; Behl B; Unger L; Haupt A; Schoemaker H; Sullivan JP; Gross G; Beninger RJ
    J Pharmacol Exp Ther; 2010 Nov; 335(2):506-15. PubMed ID: 20724485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
    Davidkova G; Zhou LW; Morabito M; Zhang SP; Weiss B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subchronic buspirone, mesulergine, and ICS 205-930 lack effects on D1 and D2 dopamine binding in the rat striatum during chronic haloperidol treatment.
    Young KA; Zavodny R; Hicks PB
    J Neural Transm Gen Sect; 1991; 86(3):223-8. PubMed ID: 1837997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover.
    Vital MA; Flório JC; Frussa-Filho R; De Lucia R; Tufik S; Palermo-Neto J
    Life Sci; 1998; 62(13):1161-9. PubMed ID: 9519797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
    Schröder U; Schröder H; Augustin W; Sabel BA
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats].
    Minematsu N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Jun; 15(3):247-52. PubMed ID: 7584718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
    Lipska BK; Weinberger DR
    Brain Res Dev Brain Res; 1993 Oct; 75(2):213-22. PubMed ID: 7903225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monosialoganglioside increased the in vivo affinity of D2 receptors for apomorphine in supersensitive rats.
    Vital MB; Frussa-Filho R; Palermo-Neto J
    Ann N Y Acad Sci; 1998 Jun; 845():428-9. PubMed ID: 9668390
    [No Abstract]   [Full Text] [Related]  

  • 20. Enhanced striatal dopamine D(2) receptor-induced [35S]GTPgammaS binding after haloperidol treatment.
    Geurts M; Hermans E; Maloteaux JM
    Eur J Pharmacol; 1999 Oct; 382(2):119-27. PubMed ID: 10528146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.